Table 2.
Patients’ characteristics by trial (N = 5209).
| Trials | FIGO | Residual Disease | |||||||
|---|---|---|---|---|---|---|---|---|---|
| I | II | III | IV | . | <1 cm | ≥1 cm | NA | . | |
| MITO-7 | 41 (8.9%) | 42 (9.1%) | 273 (59.2%) | 105 (22.8%) | NA | NA | |||
| GINECO-2007 | 0 | 0 | 78 (80.4%) | 19 (19.6%) | 1 | 14 (14.4%) | 83 (85.6%) | 1 | |
| TURBO | 0 | 19 (7.9%) | 156 (65%) | 65 (27.1%) | 173 (72.7% | 63 (26.5%)) | 2 (0.8%) | 2 | |
| JGOG-3016 | 0 | 102 (18.6%) | 364 (66.5%) | 81 (14.8%) | 258 (47.2%) | 275 (50.3%) | 14 (2.6%) | ||
| SCOTROC-4 | 118 (13.9%) | 75 (8.8%) | 549 (64.6%) | 108 (12.7%) | 300 (35.3%) | 550 (64.7%) | |||
| JGOG-3017 | 395 (66.1%) | 69 (11.5%) | 112 (18.7%) | 22 (3.7%) | 548 (91.6%) | 48 (8%) | 2 (0.3%) | ||
| NSGO-2012 | 0 | 94 (12.7%) | 533 (71.8%) | 115 (15.5%) | 317 (42.7%) | 425 (57.3%) | |||
| SCOTROC-1 | 70 (7.2%) | 127 (13%) | 645 (65.9%) | 137 (14%) | 332 (33.9%) | 647 (66.1%) | |||
| CCTG-OV.16 | 0 | 65 (9.4%) | 468 (67.4%) | 161 (23.2%) | 325 (57%) | 238 (41.8%) | 7 (1.2%) | 124 | |
Abbreviations: ‘.’: Missing information, NA: Not available.